Prior to this, AstraZeneca reported positive results from the efzimfotase alfa Phase III clinical trial programme for ...
AstraZeneca is driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly ...
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...
April 2 () - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...
Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
The company said the results support the drug’s potential to transform the treatment of hypophosphatasia and it plans to ...
A major cyberattack has targeted pharmaceutical giant AstraZeneca. Hackers claim they stole internal company data and later ...
AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results